Kawazoe, A., Kazmi, S. M. A., Xu, R., Jemielita, T., Hatogai, K., Adelberg, D. E., Tabernero, J. (2026). KANDLELIT-012: Phase 3 study of MK-1084 (a
                    <i>KRAS G12C</i>
                    inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for
                    <i>KRAS</i>
                    <i>G12C</i>
                    -mutant colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps267